

these body systems at the third step of our sequential evaluation process after the current expiration date of these listings. In order to ensure that we continue to have regulatory criteria for assessing impairments under these listings, we find that it is in the public interest to make this final rule effective on the date of publication.

Executive Order 12866

We have consulted with the Office of Management and Budget (OMB) and determined that this final rule does not meet the criteria for a significant regulatory action under Executive Order (E.O.) 12866, as amended by E.O. 13258. We have also determined that this final rule meets the plain language requirement of E.O. 12866, as amended by E.O. 13258.

Regulatory Flexibility Act

We certify that this final rule will not have a significant economic impact on a substantial number of small entities. Therefore, a regulatory flexibility analysis, as provided in the Regulatory Flexibility Act, as amended, is not required.

Paperwork Reduction Act

This final rule imposes no reporting/recordkeeping requirements necessitating clearance by OMB.

(Catalog of Federal Domestic Assistance Program Nos. 96.001, Social Security-Disability Insurance; 96.002, Social Security-Retirement Insurance; 96.004, Social Security-Survivors Insurance; 96.006, Supplemental Security Income)

List of Subjects in 20 CFR Part 404

Administrative practice and procedure, Blind, Disability benefits, Old-Age, Survivors and Disability Insurance, Reporting and recordkeeping requirements, Social Security.

Dated: June 4, 2003.

Jo Anne B. Barnhart,
Commissioner of Social Security.

■ For the reasons set forth in the preamble, part 404, subpart P, chapter III of title 20 of the Code of Federal Regulations is amended as set forth below.

PART 404—FEDERAL OLD-AGE, SURVIVORS AND DISABILITY INSURANCE (1950—)

Subpart P—[Amended]

■ 1. The authority citation for subpart P of part 404 continues to read as follows:

Authority: Secs. 202, 205(a), (b), and (d)-(h), 216(i), 221(a) and (i), 222(c), 223, 225, and 702(a)(5) of the Social Security Act (42 U.S.C. 402, 405(a), (b), and (d)-(h), 416(i), 421(a) and (i), 422(c), 423, 425, and 902(a)(5)); sec. 211(b), Pub. L. 104–193, 110 Stat. 2105, 2189.

■ 2. Appendix 1 to subpart P of part 404 is amended by revising items 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15 of the introductory text before part A to read as follows:

Appendix 1 to Subpart P of Part 404—Listing of Impairments

1. Growth Impairment (100.00): July 1, 2005
* * * * *
3. Special Senses and Speech (2.00 and 102.00): July 1, 2005
4. Respiratory System (3.00 and 103.00): July 1, 2005
5. Cardiovascular System (4.00 and 104.00): July 1, 2005
6. Digestive System (5.00 and 105.00): July 1, 2005
7. Genito-Urinary System (6.00 and 106.00): July 1, 2005
8. Hemic and Lymphatic System (7.00 and 107.00): July 1, 2005
9. Skin (8.00): July 1, 2005
10. Endocrine System (9.00 and 109.00): July 1, 2005
11. Multiple Body Systems (10.00): June 19, 2008 and (110.00): July 1, 2005
12. Neurological (11.00 and 111.00): July 1, 2005
13. Mental Disorders (12.00 and 112.00): July 1, 2005

14. Neoplastic Diseases, Malignant (13.00 and 113.00): July 1, 2005
15. Immune System (14.00 and 114.00): July 1, 2005

* * * * *

[FR Doc. 03–15599 Filed 6–19–03; 8:45 am]

BILLING CODE 4191–02–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 522 and 524

Dosage Form New Animal Drugs; Change of Sponsor; Technical Amendment

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule; technical amendment.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for four approved new animal drug applications (NADAs) from Anthony Products, Co. to Cross Vetpharm Group, Ltd.

DATES: This rule is effective June 20, 2003.

FOR FURTHER INFORMATION CONTACT: David R. Newkirk, Center for Veterinary Medicine (HFV–100), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–6967, e-mail: dnewkirk@cvm.fda.gov.

SUPPLEMENTARY INFORMATION: Anthony Products, Co., 5600 Peck Rd., Arcadia, CA 91006, has informed FDA that it has transferred ownership of, and all rights and interest in, the following four approved NADAs to Cross Vetpharm Group, Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland.

NADA Number	Trade Name	21 CFR Section
049–187	PHEN–BUTA (phenylbutazone) Vet Tablets; Phenylbutazone Tablets (Dogs)	520.1720a
122–447	FURA–SEPTIN (nitrofurazone) Soluble Dressing	524.1580b
130–136	Oxytocin Injection	522.1680
140–582	BIOCYL 50; BIOCYL 100 (oxytetracycline)	522.1662a

Accordingly, the agency is amending the regulations in §§ 522.1662a, 522.1680, and 524.1580b (21 CFR 522.1662a, 522.1680, and 524.1580b) to reflect the transfer of ownership. No

amendment of 21 CFR 520.1720a is necessary as each sponsor owns additional phenylbutazone products.

In addition, § 522.1662a is being revised to reflect current format. This

action is being taken to improve consistency between sections of the regulations.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because